TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P | %ret | 1 | 1 | 1 | -2 | 25 | 6 | -6 | -44 | -78 | -17 |
| P | %wins | 0 | 100 | 100 | 0 | 0 | 0 | 33 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3/11/24 16:15 | 3/8/24 | DBVT | Dbv Technologies S.A. | I0 | Health | BioPrd | Biological Products, (No Diag | Tasse Daniel | I0 | DO | CEO | P | 14 | 0.8300 | 0 | 17 | New | 17 | D | ||||||||||||||
2/23/15 21:41 | 2/19/15 | BLPH | Bellerophon Therapeutics, Inc. | Health | Drug | Pharmaceutical Preparations | Tasse Daniel | NJ | D | P | 300 | 12.00 | 3 | 25 | 24 | 129 | D | 2 | -2 | 25 | 6 | -6 | -44 | -78 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |